Immunotherapy in urothelial carcinoma: fade or future standard?

Immunotherapy of non-muscle-invasive bladder carcinoma by Bacillus-Calmette-Guérin (BCG) instillation is a well-established treatment option since decades. Despite this fact, the immunocellular basis was first studied in recent years. New aspects of immunotherapy, also for progressed bladder carcino...

Descripción completa

Detalles Bibliográficos
Autores principales: Breyer, Johannes, Burger, Maximilian, Otto, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071200/
https://www.ncbi.nlm.nih.gov/pubmed/27785423
http://dx.doi.org/10.21037/tau.2016.04.06
Descripción
Sumario:Immunotherapy of non-muscle-invasive bladder carcinoma by Bacillus-Calmette-Guérin (BCG) instillation is a well-established treatment option since decades. Despite this fact, the immunocellular basis was first studied in recent years. New aspects of immunotherapy, also for progressed bladder carcinoma, might follow promising research on immunological targets.

Ejemplares similares